Abstract
Introduction
To examine the comparative short-term effects of brimonidine/timolol and dorzolamide/timolol on ocular perfusion pressure and retrobulbar blood flow in patients with primary open angle glaucoma (OAG).
Methods
In a prospective, randomized, double-blind, crossover study, intraocular pressure (IOP), blood pressure (BP), ocular perfusion pressure (OPP), and retrobulbar hemodynamics were assessed in 15 patients with OAG (mean age 68.1 years, eight women) with well controlled IOP. IOP was measured by Goldman applanation tonometery and color Doppler imaging was utilized to assess the retrobulbar blood vessels before and 1 month after treatment with topical brimonidine/timolol and dorzolamide/timolol. Statistical analysis was performed by Friedman two-way analysis of variance by ranks and post-hoc Wilcoxon signed rank test for multiple comparisons with Holm’s sequential Bonferroni procedure. P values <0.05 were considered statistically significant.
Results
The Friedman test and subsequent post-hoc analysis indicated that IOP, BP, OPP, and retrobulbar blood flow velocities did not significantly differ between brimonidine/timolol and dorzolamide/timolol after 1-month treatment administration in patients with OAG and well controlled IOP.
Conclusion
In this cohort of patients with OAG, short-term treatment with brimonidine/timolol and dorzolamide/timolol results in similar effects on OPP and retrobulbar blood flow velocities.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Hollows RC, Graham PA. Intraocular pressure, glaucoma, and glaucoma suspects in a defined population. Br J Ophthalmol. 1996;50:570–577.
Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279.
Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressure. Am J Ophthalmol. 1998;126:487–497.
Harris A, Kagemann L, Ehrlich R, Rospigliosi C, Moore D, Siesky B. Measuring and interpreting ocular blood flow and metabolism in glaucoma. Can J Ophthalmol. 2008;43:328–336.
Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol. 1995;113:216–221.
Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001;119:1819–1826.
Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology. 2000;107:1287–1293.
Leske MC, Wu SY, Nemesure B, Hennis A. Incident open-angle glaucoma and blood pressure. Arch Ophthalmol. 2002;120:954–959.
Moore D, Harris A, Wudunn D, Kheradiya N, Siesky B. Dysfunctional regulation of ocular blood flow: a risk factor for glaucoma? Clin Ophthalmol. 2008;2:849–861.
Weinreb RN, Harris A, eds. Ocular Blood Flow in Glaucoma: The 6th Consensus Report of the World Glaucoma Association. Amsterdam: Kugler Publications; 2009. 1–159.
Costa VP, Harris A, Stefánsson E, et al. The effects of antiglaucoma and systemic medications on ocular blood flow. Prog Retin Eye Res. 2003;22:769–805.
Siesky B, Harris A, Brizendine E, et al. Literature review and meta-analysis of topical carbonic anhydrase inhibitors and ocular blood flow. Surv Ophthalmol. 2009;54:33–46.
Harris A, Sergott RC, Spaeth GL, Katz JL, Shoemaker JA, Martin BJ. Color Doppler analysis of ocular vessel blood velocity in normal-tension glaucoma. Am J Ophthalmol. 1994;118:642–649.
Williamson TH, Harris A. Color Doppler ultrasound imaging of the eye and orbit. Surv Ophthalmol. 1996;40:255–267.
Harris A, Williamson TH, Martin B, et al. Test/retest reproducibility of color Doppler imaging assessment of blood flow velocity in orbital vessels. J Glaucoma. 1995;4:281–286.
Quaranta L, Harris A, Donato F, Cassamali M, Semeraro F, Nascimbeni G, et al. Color Doppler imaging of ophthalmic artery blood flow velocity: a study of repeatability and agreement. Ophthalmology. 1997;104:653–658.
Macknight AD, McLaughlin CW, Peart D, Purves RD, Carré DA, Civan MM. Formation of the aqueous humor. Clin Exp Pharmacol Physiol. 2000;27:100–106.
Taki K, Kato H, Endo S, Totsuka K. Cascade of acetazolamide-induced vasodilatation. Res Comm Mol Path Pharmacol. 1999;103:240–248.
Siesky B, Harris A, Kagemann L, et al. Ocular blood flow and oxygen delivery to the retina in primary open-angle glaucoma patients: the addition of dorzolamide to timolol monotherapy. Acta Ophthalmol. 2010;88:142–149.
Januleviciene I, Ehrlich R, Siesky B, Nedzelskiené I, Harris A. Visual function, optic nerve structure, and ocular blood flow parameters after 1 year of glaucoma treatment with fixed combinations. Eur J Ophthalmol. 2009;19:790–797.
Harris A, Migliardi R, Rechtman E, Cole CN, Yee AB, Garzozi HJ. Comparative analysis of the effects of dorzolamide and latanoprost on ocular hemodynamics in normal tension glaucoma patients. Eur J Ophthalmol. 2003;13:24–31.
Harris A, Jonescu-Cuypers CP, Kagemann L, et al. Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma. Am J Ophthalmol. 2001;132:490–495.
Lachkar Y, Migdal C, Dhanjil S. Effect of brimonidine tartrate on ocular hemodynamic measurements. Arch Ophthalmol. 1998;116:1591–1594.
Inan UU, Ermis SS, Yucel A, Oztürk F. The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial. Acta Ophthalmol Scand. 2003;81:155–160.
Puerto-Hernández B, Rebolleda G, García-Pérez JL, Muñoz-Negrete FJ, González-Gordaliza C. Effect on ocular blood flow of Combigan® versus placebo in patients with ocular hypertension. Arch Soc Esp Oftalmol. 2011;86:42–46.
Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47:2917–2923.
Liu CJ, Cheng CY, Ko YC, Hsu WM. Diurnal intraocular pressure and blood pressure with two dosing regimens of brimonidine in normal tension glaucoma. J Chin Med Assoc. 2004;67:465–471.
Sung KR, Lee S, Park SB, et al. Twenty-four hour ocular perfusion pressure fluctuation and risk of normal-tension glaucoma progression. Invest Ophthalmol Vis Sci. 2009;50:5266–5274.
Author information
Authors and Affiliations
Corresponding author
Additional information
To view enhanced content go to www.advancesintherapy.com
This article is published with open access at Springerlink.com
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Siesky, B., Harris, A., Ehrlich, R. et al. Short-Term Effects of Brimonidine/Timolol and Dorzolamide/Timolol on Ocular Perfusion Pressure and Blood Flow in Glaucoma. Adv Therapy 29, 53–63 (2012). https://doi.org/10.1007/s12325-011-0092-3
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-011-0092-3